Rothman Institute Orthopaedics
The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.
Inclusion Criteria: * Aged 40-80 years. * Undergoing thumb basal joint arthroplasty (BJA) * Able to provide informed consent. * Willing to comply with the study procedures. Exclusion Criteria: * History of substance abuse or chronic opioid use. * Known allergies to acetaminophen, oxycodone, or suzetrigine. * Severe renal or hepatic dysfunction * Estimated glomerular filtration rate less than 15 ml/min/1.73m\^2 * History of kidney transplant * Child-Pugh Class C * History of liver failure * Active hepatitis that can adversely influence hepatic function * Has had prior surgery on the study ha…
Participants will receive the recommended dosing for suzetrigine, which consists of a 100 mg oral loading dose taken in the recovery room prior to discharge, followed by 50 mg doses taken orally every 12 hours for 5 days, totaling 11 doses.
As part of the multimodal pain regimen, participants will also receive acetaminophen (Tylenol) (500 mg, every 4 hours, or 1000 mg, every 8 hours)
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.